Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in NTLA.

← Back to Free Index

NTLA

Analysis as of: 2026-05-28

Intellia Therapeutics, Inc.

Clinical-stage gene-editing biotech developing in vivo CRISPR therapies led by lonvo-z for hereditary angioedema and nex-z for transthyretin amyloidosis.

ai biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Approval Path Opens, Adoption Decides Outcome

The HAELO win moved the story from science proof to approval-and-launch execution. A durable rerating now depends on payer design, treatment-center conversion and whether ATTR becomes a real second franchise rather than residual option value.

Analysis

Thesis

The 5-year upside is a category shift: if lonvo-z clears FDA and gains payer-backed adoption, Intellia can move from a cash-burning CRISPR platform to a rare-disease franchise with reusable reimbursement, treatment-center and clinical-data infrastructure, while nex-z and selective licensing add a second leg of value.

Last Economy Alignment

AI should improve discovery, trial operations and patient-finding, but value capture here sits in regulated human data, IP, CMC execution and trust with payers and treatment centers. Low software commoditization exposure helps, yet approval and safety gates keep the score below infrastructure-grade AI winners.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

4.6x (from 4 most recent analyses)

Reasoning

The upside is a rerating from platform optionality to franchise value. Lonvo-z now has real late-stage credibility, and a successful launch could create reusable payer, center and safety infrastructure for follow-on liver programs. I keep the outcome below top rare-disease compounders because first-generation in vivo editing still faces trust, label and reimbursement friction, and ATTR still competes against entrenched silencer therapies.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The key risk is conversion risk: positive science has to survive FDA review, earn a usable label, secure reimbursement and scale through a small set of centers before cash burn forces more financing. If lonvo-z works commercially, the platform rerates; if uptake is niche and ATTR stays impaired, the stock can remain a cash-plus-one-asset story.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No material official disclosure arrived after the May 11, 2026 Q1 update, so the setup is largely unchanged heading into June.
The June 12, 2026 EAACI HAELO presentation is now the next near-term repricing event, with durability and safety detail in focus.
No new disclosed safety setback has emerged since screening resumed in MAGNITUDE and MAGNITUDE-2, but ATTR remains only partially re-opened.

Thesis update

The thesis is more concrete than in the prior run: positive Phase 3 HAE data and BLA initiation shifted the story from scientific possibility toward approval-and-launch conversion. ATTR still matters, but lonvo-z now anchors the equity case more explicitly.

Forecast update

De-risking improved the quality of the story, but dilution and a more conservative timing credit for ATTR pull the upside path toward steadier franchise building rather than a sharper platform rerating.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.41

They control hard-to-copy clinical data, regulatory know-how and a possible one-time edit that could replace years of chronic treatment. AI should help the science and operations, but FDA gates, safety trust and payer adoption still decide how much value they keep.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$26.65

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research